Sector News

China's pollution crackdown creating pharma supply issues

February 21, 2018
Life sciences

China has closed tens of thousands of manufacturing plants across the country in an effort to reduce serious air pollution, and generics maker Stada says China’s crackdown has created supply problems.

Ronald Seeliger, eastern European regional chief for German generics maker Stada, told Bloomberg that China’s actions have interrupted deliveries, making it more important for the drugmaker to take some production in-house, although it still must rely on Chinese API makers.

“That’s having a big, big impact on us,” Seeliger told the news service last week. “Stada is seeking to insource many more products, to produce them in-house for better availability, better costs, reliable quality and for better logistics.”

One project that will help that effort, Seeliger said, is the a new packaging plant that Stada’s Hemofarm unit in Serbia will officially open this year. The €22 million ($27 million) plant in Vršac, Serbia, will allow the drugmaker to separate production from packaging. Stada has said the 600 square meter facility can fill 75 million ampoules annually.

The supply issues come even as the drugmaker is looking to expand in Eastern Europe following its $6.7 billion takeover by private equity partners Bain Capital and Cinven, who have replaced the board and named drug industry veteran Claudio Albrecht as its new CEO.

According to news reports, Chinese officials last fall closed up to 40% of the country’s manufacturing sites at some point for inspections of environmental standards. NPR earlier reported more than 80,000 factories were issued fines or criminal offenses as a result of their emissions, as safety officials did rolling inspections through dozens of Chinese provinces, causing supply interruptions for companies worldwide.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).